The pharmaceutical colossus Novartis accused between April and the end of June an erosion of 1% of its turnover to 12.78 billion dollars (12.49 billion francs).
The contribution of the core Innovative Medicines business contracted by 1% to 10.46 billion, while Sandoz generics and biosimilars brought in 2.32 billion, down 3%.
Basic net profit, adjusted for any factor considered non-recurring, eroded 2% to 3.43 billion, said a press release released on Tuesday.
The performance is more or less in line with the projections of the analysts consulted by AWP, who articulated on average revenues of 12.98 billion at group level, including 10.56 billion from original preparations and 2.27 billion from Sandoz. Net profitability is higher than the expected 3.36 billion.
The management somewhat reformulates its ambitions for the current year as a whole, confirming that for the group.
/ATS
